Excision BioTherapeutics
Philadelphia
About Excision BioTherapeutics
Excision BioTherapeutics is a private company focused on developing advanced gene-editing therapeutics to address the medical need for the treatment of life-threatening diseases caused by viral infections. They develop gene-editing medicines that eradicate or disrupt viral genes in human patients. Their mission is to advance gene-editing therapeutics for our indications into safe and efficacious medicines that will greatly improve the lives of infected individuals around the world.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $77.6M
- Funding stage: Early Stage Venture
- Last round: Grant (Sep 2022)
- Website: excision.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/excision-biotherapeutics-99633 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.